Cumberland Pharmaceuticals Inc: Form 10-Q for the period ended Sep 30, 2015
Filed with the SEC on Nov 6, 2015 and accepted by EDGAR at Nov 6, 2015, 17:12 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2015-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2015-07-01 to 2015-09-30 | $7.9m | us-gaap:SalesRevenueNet |
| Revenue | 9 months2015-01-01 to 2015-09-30 | $25.5m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months2015-07-01 to 2015-09-30 | $980.2k | us-gaap:CostOfGoodsSold |
| Cost of revenue | 9 months2015-01-01 to 2015-09-30 | $3.4m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months2015-07-01 to 2015-09-30 | $757.4k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2015-01-01 to 2015-09-30 | $3.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2015-07-01 to 2015-09-30 | $270.9k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2015-01-01 to 2015-09-30 | $948.9k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2015-07-01 to 2015-09-30 | $19.8k | us-gaap:InterestExpense |
| Interest expense | 9 months2015-01-01 to 2015-09-30 | $53.9k | us-gaap:InterestExpense |
| Income tax | 3 months2015-07-01 to 2015-09-30 | $193.4k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2015-01-01 to 2015-09-30 | $530.9k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2015-07-01 to 2015-09-30 | $126.6k | us-gaap:NetIncomeLoss |
| Net income | 9 months2015-01-01 to 2015-09-30 | $580.3k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2015-07-01 to 2015-09-30 | $0.01 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2015-01-01 to 2015-09-30 | $0.03 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2015-07-01 to 2015-09-30 | $0.01 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2015-01-01 to 2015-09-30 | $0.03 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2015-07-01 to 2015-09-30 | 16,996,376 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2015-01-01 to 2015-09-30 | 17,193,854 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2015-01-01 to 2015-09-30 | $4.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2015-01-01 to 2015-09-30 | $96.8k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months2015-01-01 to 2015-09-30 | $4.7m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2015-09-30 | $38.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2015-09-30 | $67.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2015-09-30 | $92.1m | us-gaap:Assets |
| Current liabilities | At period end2015-09-30 | $11.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2015-09-30 | $14.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2015-09-30 | $77.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-15-008469. Last ingested by Listed: Nov 11, 2026, 03:05 ET. Listed shows no prices and gives no investment advice.